Shi Chunmeng, Zhu Ying, Su Yongping, Chung Leland W K, Cheng Tianmin
State Key Laboratory of Trauma, Burns and Combined Injury, Institute of Combined Injury, Chongqing Engineering Research Center for Nanomedicine, Third Military Medical University, Chongqing, China.
Drug Discov Today. 2009 Jan;14(1-2):25-30. doi: 10.1016/j.drudis.2008.11.001. Epub 2008 Dec 26.
Beta2-microglobulin, a MHC class I subunit, is found to act similarly to a prototypical oncogenic factor capable of stimulating growth and progression of various cancers and plays a key regulatory role in stimulating cancer bone metastasis. Free beta2M in serum or urine has been regarded as an independent biomarker in several cancers. Specific antibodies to beta2M have remarkable tumoricidal activity for both solid tumors and blood malignancies and are shown to be selective to tumor cells, but caused no toxicity in normal cells. These surprising data strongly suggest that beta2M is a promising new therapeutic target for human cancers.
β2-微球蛋白是一种MHC I类亚基，被发现其作用类似于一种能够刺激各种癌症生长和进展的典型致癌因子，并在刺激癌症骨转移中起关键调节作用。血清或尿液中的游离β2M已被视为多种癌症中的独立生物标志物。针对β2M的特异性抗体对实体瘤和血液恶性肿瘤均具有显著的杀肿瘤活性，且对肿瘤细胞具有选择性，但对正常细胞无毒性。这些惊人的数据强烈表明，β2M是人类癌症一个有前景的新治疗靶点。
